Jeffrey A. Stafford, PhD
President and Chief Executive Officer
Jeff brings over 25 years of success in drug discovery to his role as President and CEO of Jecure Therapeutics. Previously, he was the founding CSO of Quanticel Pharmaceuticals, a drug discovery company based on the epigenetic targeting of cancer stem cells and tumor heterogeneity through the pioneering use of single cell genomics. In 2011 Quanticel entered into an exclusive build-to-buy collaboration with Celgene and was then acquired by Celgene in 2015. Jeff has held senior scientific and management positions at Quanticel, Takeda San Diego, Syrrx, and GlaxoSmithKline, and his teams have discovered 9 development candidates that have advanced into clinical trials, including the marketed drugs, Votrient™ (pazopanib), Nesina™ (alogliptin) and the Phase 3 investigational drug, remimazolam (CNS-7056).
Jeff received a B.S. in Chemistry from UCLA and a Ph.D. in Chemistry from Cornell University. He completed an NIH Postdoctoral Fellowship at UC Berkeley.
James M. Veal, PhD
Chief Scientific Officer
Jim has over 25 years of drug discovery experience and began his career in 1991 at Glaxo Research Institute. During his years at Glaxo, GlaxoWellcome, and GSK, he worked on a range of receptor and enzymatic targets including protein kinases for the treatment of inflammation and cancer. In 2003, he joined Serenex Inc. and became the Senior Director of Structural Chemistry and Informatics. Serenex was acquired in 2008 by Pfizer for its proteomics platform and drug discovery programs. He then moved to Pamlico Pharmaceuticals as Vice President of Research, leading drug discovery efforts targeted at GPCR receptors. Prior to joining Jecure Therapeutics, he was a Distinguished Research Fellow at Quanticel Pharmaceuticals where he played an integral role in the discovery of multiple development candidates that target cancer stem cells. Jim has made significant contributions to the discovery of 7 compounds that have advanced to clinical trials including Votrient™ (pazopanib), Tykerb™ (lapatinib), SNX-5422, and Huanmideji. He is an author of numerous scientific publications and an inventor on multiple issued patents.
Jim received a B.A. in Chemistry from Duke University and a Ph.D. from the Institute of Molecular Biophysics at Florida State University.
Gretchen Bain, PhD
Vice President of Biology
Gretchen has over 15 years of experience in biotech and pharma drug discovery research, beginning her career at Merck Research Labs. In 2005, she joined Amira Pharmaceuticals as one of its founding scientists and led the in vitro pharmacology group, directing research programs in asthma and pulmonary fibrosis that produced 5 clinical candidates. Gretchen was instrumental in establishing pharmacodynamics assays that were used in Phase I clinical studies to demonstrate target engagement and guide dose selection. In 2011 Amira was acquired by Bristol-Myers Squibb, and then as Executive Director of Biology, she led research on anti-fibrotic mechanisms of LPA1 receptor antagonism that directly informed the clinical biomarker strategy for BMS-986020 in IPF patients. Prior to joining Jecure, Gretchen was a founding scientist of PharmAkea Therapeutics where she and her biology team contributed to the discovery and development of two clinical candidates, including a small molecule LOXL2 inhibitor for the treatment of IPF and chronic kidney disease.
Gretchen received a B.A. in Biology from Pomona College, Claremont, CA and a Ph.D. in Biology from University of California, San Diego.